Pentoxifylline treatment for protecting diabetic retinopaty in children with type 1 diabetes

Basit Öğe Kaydı
dc.contributor.authorBaykara, Murat
dc.contributor.authorAtabek, Mehmet Emre
dc.contributor.authorEklioglu, Beray Selver
dc.contributor.authorKurtoglu, Selim
dc.date.accessioned2024-02-23T14:29:49Z
dc.date.available2024-02-23T14:29:49Z
dc.date.issued2013
dc.departmentNEÜen_US
dc.description.abstractObjective: The purpose of this study was to determine whether oral pentoxifylline (PTX) would improve retinal microvascular hemodynamics in children with type 1 diabetes mellitus (DM). Patients and methods: Non-invasive ultrasonographic measurements were made in 56 type 1 diabetic patients. The diabetic patients were matched first in terms of age, diabetes duration, then one individual within each pair was randomized into a pentoxifylline group and a control group. Pentoxifylline was administered for 6 months. We investigated the change of peak systolic velocity (PSV), end diastolic velocity (EDV), pulsatility index (PI), and resistivity index (RI) of central retinal artery (CRA) at 6 months after pentoxifylline. We investigated the relationship between PI, RI and carotide cross-sectional compliance (C-CSC). Results: In comparison to changes in CRA measurements between the two groups, the pentoxifylline treatment group had significantly lower PI values (p=0.01). The RI, PSV and EDV were lower in pentoxifylline group but not statistifically different. There was a positive correlation between CRA PSV and carotid V-max (cm/s) (r=0.29, p=0.02) and also C-CSC (r=0.27, p=0.03). In addition, there was a positive correlation between PI and C-CSC (r=0.3, p=0.02). In the pentoxifylline group there was a significant reduction in systolic blood pressure, diastolic blood pressure, microalbuminuria and an increase in HDL level. Conclusion: Our results suggest that pentoxifylline may have a protective action for diabetic retinopathy and might modulate risk factors for atherosclerosis in type 1 diabetes.en_US
dc.identifier.doi10.1515/jpem-2012-0166
dc.identifier.endpage24en_US
dc.identifier.issn0334-018X
dc.identifier.issn2191-0251
dc.identifier.issue1.Şuben_US
dc.identifier.pmid23457307en_US
dc.identifier.scopus2-s2.0-84878284530en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage19en_US
dc.identifier.urihttps://doi.org/10.1515/jpem-2012-0166
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14866
dc.identifier.volume26en_US
dc.identifier.wosWOS:000316895000003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWalter De Gruyter Gmbhen_US
dc.relation.ispartofJournal Of Pediatric Endocrinology & Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCentral Retinal Arteryen_US
dc.subjectCommon Carotid Arteryen_US
dc.subjectPentoxifyllineen_US
dc.subjectType 1 Diabetesen_US
dc.titlePentoxifylline treatment for protecting diabetic retinopaty in children with type 1 diabetesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu